New York, USA, July 24, 2024 (GLOBE NEWSWIRE) -- DelveInsight’s report includes a comprehensive understanding of current treatment practices, Leigh syndrome emerging drugs, market share of individual therapies, and current and forecasted Leigh syndrome market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Discover which therapies are expected to grab Leigh syndrome market share @ Leigh syndrome is a rare genetic disorder affecting neurometabolism. It is marked by the deterioration of the central nervous system, including the brain, spinal cord, and optic nerve.
Typically, Leigh syndrome is passed down as an autosomal recessive trait, but it can also be inherited through X-linked recessive or maternal transmission due to mitochondrial DNA mutations. The symptoms of Leigh syndrome often worsen quickly. Initial signs may include difficulty sucking, loss of head control and motor skills, decreased appetite, vomiting, and seizures.
As the disease advances, it may cause muscle weakness, reduced muscle tone, spasticity, movement disorders, cerebellar ataxia, and peripheral neuropathy. Complications can affect respiratory, heart, and kidney functions. Diagnosing Leigh syndrome involves a detailed clinical evaluation and various specialized tests, particularly advanced imaging methods.
MRI or CT scans of the brain can reveal abnormalities in specific areas such as the basal ganglia, brain s.